InterMune joins M&A fray
InterMune appears to be the latest M&A target. Bloomberg reports that drugmakers including GlaxoSmithKline, Actelion, Sanofi and Roche are rumored to be among a host of companies making a pitch to buy the business and own the company's experimental drug for idiopathic pulmonary fibrosis (IPF). William Blair analyst Katherine Xu tells Bloomberg that the company's experimental treatment looks to be better than Boehringer Ingelheim's experimental IPF therapy, echoing an opinion Jefferies analyst Eun Yang voiced in May.
JMP Securities analyst Liisa Bayko tells Bloomberg that a natural match would be a company with a foothold in the respiratory field.